HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

Keita Yamana; Riku Kawasaki; Kousuke Kondo; Hidetoshi Hirano; Shogo Kawamura; Yu Sanada; Kaori Bando; Anri Tabata; Hideki Azuma; Takushi Takata; Yoshinori Sakurai; Hiroki Tanaka; Tomoki Kodama; Seiji Kawamoto; Takeshi Nagasaki; Atsushi Ikeda

doi:10.1039/d3na00028a

HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

Nanoscale Adv. 2023 Jun 1;5(15):3857-3861. doi: 10.1039/d3na00028a. eCollection 2023 Jul 25.

Authors

Affiliations

¹ Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan riku0528@hiroshima-u.ac.jp aikeda@hiroshima-u.ac.jp.
² Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan.
³ Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University 3-3-138 Sugimoto, Sumiyoshi-ku Osaka City 558-8585 Japan.
⁴ Program of Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan.

Abstract

The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.